Back to top
more

Gilead Sciences (GILD)

(Delayed Data from NSDQ)

$83.04 USD

83.04
5,653,121

+0.83 (1.01%)

Updated Sep 26, 2024 04:00 PM ET

After-Market: $83.05 +0.01 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (84 out of 252)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Gilead (GILD) Application for HIV Drug Validated in EU

Gilead Sciences, Inc. (GILD) announced that the company's Marketing Authorization Application for once-daily single tablet for the treatment of HIV-1 infection in adults has been fully validated by the European Medicines Agency.

    Gilead (GILD) Application for HIV Drug Validated in EU

    Gilead Sciences, Inc. (GILD) announced that the company's Marketing Authorization Application for once-daily single tablet for the treatment of HIV-1 infection in adults has been fully validated by the European Medicines Agency.

      The Zacks Analyst Blog Highlights: Merck, Celgene, Gilead Sciences, Seattle Genetics and Vanda Pharmaceuticals

      The Zacks Analyst Blog Highlights: Merck, Celgene, Gilead Sciences, Seattle Genetics and Vanda Pharmaceuticals

        5 Drug Stocks Well Poised to Beat Q2 Earnings Estimates

        The NYSE ARCA Pharmaceutical Index has risen almost 9.8% year to date.

          Arpita Dutt headshot

          5 Pharma & Biotech Stocks That Could Be Big Winners in Q2 Earnings

          Here is a look at 5 pharma and biotech stocks including Merck (MRK) that are expected to post a positive earnings surprise in Q2.

            Arpita Dutt headshot

            Biotech Stock Roundup: Arena Shoots Up on Study Data, CELG Inks Immuno-Oncology Deal

            Arena (ARNA) saw it shares shoot up on mid-stage data on its pulmonary arterial hypertension drug while quite a few companies provided regulatory updates.

              J&J (JNJ) to Commence Pharma Q2 Earnings Season: What's Up?

              Johnson & Johnson (JNJ), a healthcare bellwether, will report second-quarter 2017 results on Jul 18.

                The Zacks Analyst Blog Highlights: Wells Fargo, Broadcom, Gilead, NextEra Energy and Emerson Electric

                The Zacks Analyst Blog Highlights: Wells Fargo, Broadcom, Gilead, NextEra Energy and Emerson Electric

                  Mark Vickery headshot

                  Top Stock Reports for Wells Fargo, Broadcom & Gilead

                  Today's Research Daily features new research reports on 16 major stocks, including Wells Fargo (WFC), Broadcom (AVGO) and Gilead (GILD).

                    Galapagos-Gilead Begin Phase II Study on Uveitis Candidate

                    Galapagos NV (GLPG) has announced initiation of a new phase II study, evaluating its lead pipeline candidate filgotinib for treatment of adult patients with non-infectious uveitis.

                      Arpita Dutt headshot

                      Biotech Stock Roundup: EU Nod for Regeneron RA Drug, Portola Soars on FDA Nod

                      Key highlights in the biotech sector include FDA approval for Portola's (PTLA) anticoagulant and EU approval for Regeneron's rheumatoid arthritis (RA) drug.

                        Gilead's (GILD) HCV Drug Application Accepted in the EU

                        Gilead Sciences, Inc. (GILD) announced that the CHMP has adopted a positive opinion on the company's application for HCV drug Vosevi.

                          AbbVie's HCV Combo Drug Gets Positive CHMP Opinion in EU

                          AbbVie Inc. (ABBV) announced that the CHMP of the EMA has recommended marketing approval of its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P).

                            Stock Market News for June 23, 2017

                            The Nasdaq finished in the green for consecutive sessions on Thursday, boosted primarily by gain in health care shares

                              Tracey Ryniec headshot

                              How to Find the Best Value Stocks

                              A great value stock isn't just a cheap stock. Tracey uses a "secret sauce" to find the hidden gems among the cheap stocks.

                                Arpita Dutt headshot

                                Biotech Stock Roundup: Clovis Soars on Rubraca Data, Seattle Hit by Study Halt

                                Key highlights in the biotech sector include positive data on Clovis' (CLVS) PARP inhibitor, Rubraca.

                                  Gilead's (GILD) HBV Drug Vemlidy Receives Approval in Canada

                                  Health Canada granted a Notice of Compliance (NOC) for Vemlidy 25mg tablets, a once-daily treatment for adults with chronic HBV infection with compensated liver disease.

                                    Is Gilead Sciences a Great Stock for Value Investors?

                                    Let's see if Gilead Sciences Inc. (GILD) stock is a good choice for value-oriented investors right now from multiple angles.

                                      Epizyme Provides Positive Interim Data on EZH2 Inhibitor

                                      Epizyme, Inc. (EPZM) announced positive interim data from an ongoing phase II study evaluating pipeline candidate tazemetostat as a monotherapy in patients with relapsed or refractory follicular lymphoma or diffuse large B-cell lymphoma

                                        Arpita Dutt headshot

                                        Biotech Stock Roundup: Management Changes at Biogen, Alexion, GILD Files HIV Drug

                                        Key highlights in the biotech sector include management changes for Biogen (BIIB) and Alexion as well as a regulatory filing for Gilead's HIV regimen.

                                          Gilead (GILD) Submits NDA for HIV Combination Therapy Regimen

                                          Gilead Sciences, Inc. (GILD) announced that it has submitted a NDA to the FDA for an investigational HIV combination therapy regimen.

                                            The Zacks Analyst Blog Highlights: Gilead, BP, Dow Chemical, America Movil and MetLife

                                            The Zacks Analyst Blog Highlights: Gilead, BP, Dow Chemical, America Movil and MetLife

                                              Sheraz Mian headshot

                                              Top Stock Reports for Gilead, BP & Dow Chemical

                                              Today's Research Daily features new research reports on 17 major stocks, including Gilead (GILD), BP (BP), and Dow Chemical (DOW).

                                                Why Is Gilead Sciences (GILD) Down 3.5% Since the Last Earnings Report?

                                                Gilead Sciences (GILD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                                                  Gilead Single Tablet Regiment for HIV Good in Phase III

                                                  Gilead Sciences, Inc. (GILD) reported positive results on four phase III studies evaluating bictegravir in combination with FTC/TAF as a single tablet regimen for HIV infection.